Syneos Health (NASDAQ:SYNH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “
SYNH has been the topic of a number of other reports. Barclays reaffirmed an “equal weight” rating and set a $43.00 price target (up from $40.00) on shares of Syneos Health in a research report on Thursday, March 1st. Credit Suisse Group lowered their price target on shares of Syneos Health from $68.00 to $54.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 14th. Robert W. Baird set a $46.00 price target on shares of Syneos Health and gave the stock a “buy” rating in a research report on Thursday, November 16th. BidaskClub raised shares of Syneos Health from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Finally, Wells Fargo & Co raised shares of Syneos Health from a “market perform” rating to an “outperform” rating in a research report on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Syneos Health has a consensus rating of “Buy” and an average target price of $49.78.
In other Syneos Health news, CAO Christopher L. Gaenzle sold 1,470 shares of the stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $41.00, for a total transaction of $60,270.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.24% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Municipal Employees Retirement System of Michigan acquired a new stake in shares of Syneos Health in the 4th quarter valued at approximately $741,000. Geode Capital Management LLC acquired a new stake in shares of Syneos Health in the 4th quarter valued at approximately $23,570,000. Finally, Globeflex Capital L P acquired a new stake in shares of Syneos Health in the 4th quarter valued at approximately $210,000.
WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/14/syneos-health-synh-stock-rating-lowered-by-zacks-investment-research.html.
Syneos Health Company Profile
Syneos Health, Inc, formerly INC Research Holdings, Inc, is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.